Study of Dose-Effect of COL-121 Ointment in Patients With Plaque-Type Psoriasis

Completed · Phase 2 · Has a placebo group

Conditions studied: Plaque-type Psoriasis

In brief

Low doses of topically administered vitamin D analogs have been shown to have an anti-psoriatic effect without the risk of hypercalcemia. Calcipotriol, the most thoroughly studied of the vitamin D analogs, was first approved in Europe in the early 1990s. It has been shown to be comparable or slightly more effective than class II corticosteroid ointments. However, patients had reduced levels of parathyroid hormone; mean serum and urine calcium were increased during treatment and hypercalciuria was observed. These effects were reversible with discontinuation of therapy. Thus, while calcipotriol ointment was shown to be effective, the potential for alterations in calcium homeostasis have limited its use to 100 g of ointment per week (0.5 mg calcipotriol/week). Work has continued on the creation of new vitamin D analogs, such as COL-121, with the intent of eliminating the adverse effects of hypercalcemia and hypercalciuria with a compound that is more stable and more easily administered.

Key facts

Study ID

NCT00625326

Run by

Deltanoid Pharmaceuticals

People needed

321

Starts

2008-01-01

Expected to finish

2009-06-01

Last updated by the study team

2011-04-27

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Psoriasis must affect at least 2% and not more than 10% of the subject's body surface area, excluding the face and scalp
• Subject must have 2 to 4 target plaques on the area to be treated, excluding the face and scalp.
• Subjects who are women of childbearing potential must have a negative pregnancy test and be non-lactating.
• Subjects who are women of childbearing potential must utilize one of the following methods of birth control throughout the study: IUD, diaphragm, a condom, a spermicidal gel or foam, oral contraceptives (provided subject has been utilizing this method for at least 4 months prior to Visit 1 and has not changed the brand within this period). Subjects may also participate if they are surgically sterilized, in a monogamous relationship with a sterile partner, or abstain from sexual intercourse during the course of the study.
• Subjects must be in good general health and free of any disease state or physical condition that, in the investigator's opinion, may interfere with study evaluations or exposes the subject to unacceptable risk by study participation.
• Subject must be willing and able to apply the study medication as directed, comply with the study instructions, and commit to all the follow-up visits for the duration of the study.
• Subjects must sign an informed consent form.

You may not qualify if…

• Subjects who have guttate, pustular, erythrodermic or other non-plaque types of psoriasis.
• Subjects who have spontaneously improving or rapidly deteriorating plaque psoriasis.
• Subjects who have used systemic immunomodulatory therapy known to affect psoriasis and to typically decrease immune cell populations (e.g., alefacept) within the previous 40 weeks.
• Subjects who have used any systemic immunomodulatory therapy known to affect psoriasis and to NOT typically decrease immune cell populations (e.g., etanercept) within the previous 16 weeks.
• Subjects who have used any photo-therapy (including laser), photo-chemotherapy or systemic psoriasis therapy (e.g., systemic corticosteroids, methotrexate, retinoids, cyclosporine) within the previous 12 weeks.
• Subjects who have had prolonged exposure to natural or artificial sources of ultraviolet radiation within the previous 3 weeks or are intending to have such exposure during the study, thought by the investigator likely to modify the subject's plaque psoriasis.
• Subjects who have used topical anti-psoriatic therapy (including topical retinoids) on the areas to be evaluated within the previous 2 weeks.
• Subjects who have used emollients/moisturizers on the areas to be evaluated within the previous 1 day.
• Subjects who have untreated bacterial, tubercular, fungal or viral lesions of the skin on the areas to be evaluated.
• Subjects who have known sensitivity to a component of the study medication or to topical or systemic vitamin D.
• Subjects who have any significant condition such as diseases of the hepatic, renal, endocrine, musculoskeletal, or nervous system, or any gross physical impairment.
• Subjects who have taken a vitamin D supplement that exceeds 400 IU per day in the previous 30 days.
• Subjects who have taken a calcium supplement that exceeds 1200 mg per day in the previous 30 days.
• Subjects who are using lithium or Plaquenil.
• Subjects who are using beta-blocking medication or thiazide diuretics whose dose has not been stable for at least 12 weeks.
• Subjects who have a history of hypercalcemia or evidence of vitamin D toxicity.
• Subjects who are currently being treated for malignancy or have been diagnosed with melanoma within the past 5 years.
• Subjects who have received any investigational treatment(s) within the previous 30 days.

Where it is running

• East Bay Dermatology Medical Group — Fremont, California, United States
• Dermatology Research Associates — Los Angeles, California, United States
• Skin Surgery Medical Group, Inc. — San Diego, California, United States
• Dermatology Specialists, Inc. — Vista, California, United States
• Cherry Creek Research, Inc. — Denver, Colorado, United States
• Longmont Medical Research Network — Longmont, Colorado, United States
• The Savin Center, PC — New Haven, Connecticut, United States
• International Dermatology Research, Inc. — Miami, Florida, United States
• MedaPhase, Inc. — Newnan, Georgia, United States
• Dermatology Specialists — Louisville, Kentucky, United States
• Michigan Center for Skin Care Research — Clinton Township, Michigan, United States
• Grekin Skin Institute — Warren, Michigan, United States
• Academic Dermatology Associates — Albuquerque, New Mexico, United States
• Northwest Cutaneous Research Specialists — Portland, Oregon, United States
• Philadelphia Institute of Dermatology — Flourtown, Pennsylvania, United States
• DermResearch, Inc. — Austin, Texas, United States
• Dermatology Associates of San Antonio — San Antonio, Texas, United States
• Dermatology Research Center — Salt Lake City, Utah, United States
• The Education & Research Foundation, Inc. — Lynchburg, Virginia, United States
• Premier Clinical Research — Spokane, Washington, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.